0.00Open0.14Pre Close0 Volume88 Open Interest9.50Strike Price0.00Turnover488.30%IV44.31%PremiumJul 26, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.14Extrinsic Value100Contract SizeAmericanOptions Type0.1529Delta0.1182Gamma47.71Leverage Ratio-0.1351Theta0.0000Rho7.30Eff Leverage0.0010Vega
Altimmune Stock Discussion
Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology
Altimmune (Nasdaq: ALT) has published data from a 12-week clinical trial of pemvidutide, a GLP-1/glucagon dual receptor agonist, in the Journal of Hepatology. The study focused on metabolic dysfunction-associated steatotic liver disease (MASLD). Key findings include:
- Up to 68.5% relative reduction in liver fat con...
Larger Image: tradingview.com...
$Altimmune(ALT.US)$
No comment yet